Scientists since Darwin have known that whales are mammals whose ancestors walked on land. In the past 15 years, researchers led by Hans Thewissen of the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) have identified a series of intermediate fossils documenting whale's dramatic evolutionary transition from land to sea.

But one step was missing: The identity of the land ancestors of whales.

The African Mousedeer (also called Chevrotain), for example, is known to jump in water when in danger and move around at the bottom, but it is not closely related to whales.

COPENHAGEN, Denmark, December 20 /PRNewswire/ --

- Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507 for the Treatment of Sarcoma

Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

GAITHERSBURG, Maryland, December 20 /PRNewswire/ --

- Company also Establishes New Site Leadership Team at Cambridge Facility

Continuing the solidification of its role as the global biologics unit for AstraZeneca plc (AZ), MedImmune today announced that Andrew D. Skibo has joined the company as senior vice president, engineering and JoAnn Suzich, Ph.D., a 19-year veteran of the company, has been promoted to vice president, research and development, infectious disease. In addition, MedImmune announced that it has established a new site leadership team at its Cambridge facilities as a part of the plan to integrate the former Cambridge Antibody Technology (CAT) organization into AZ's new global biologics unit, functioning under the name MedImmune.

SAN MATEO, California, December 20 /PRNewswire/ --

- With Photo

- NetSuite CEO Zach Nelson Rings Opening Bell at New York Stock Exchange

NetSuite Inc. (NYSE: N), today announced the initial public offering of 6,200,000 shares of its common stock at a price of US$26.00 per share. Its CEO Zach Nelson rang the opening bell at the New York Stock Exchange.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071220/AQTH078) (Logo: http://www.newscom.com/cgi-bin/prnh/20021024/SFTH024LOGO)

Global warming and other human-caused ecological changes are outpacing the ability of species to adapt, resulting in greater threats of disease, reduced diversity in plant and animal communities, and an overall loss of natural heritage, according to research presented in the Jan. 3, 2008, edition of Molecular Ecology.

The Special Issue includes 38 peer-reviewed articles and is dedicated to research presented at the conference – “Evolutionary Change in Human-altered Environments” – sponsored by the UCLA Institute of the Environment.

GREENSBORO, North Carolina, December 20 /PRNewswire/ --

PARIS, December 20 /PRNewswire/ -- iDOO.com is one of the first European portals to offer OpenID, a new service allowing any web surfer to use a single Internet address. The site's web server, http://www.openidoo.com, is available in Beta version.

Among the main developments in frequent surfing habits, one of the more laborious aspects is the daily connection to Internet sites. Users are waiting for improvements: simpler, faster connection without the risk of making mistakes or forgetting multiple user names and/or passwords.

A new service that helps web surfers identify themselves on the web. The principle is simple:

SAN DIEGO, December 20 /PRNewswire/ --

- Increases First Quarter Fiscal 2008 Revenue and Earnings per Share Guidance

Qualcomm Incorporated (Nasdaq: QCOM) today updated its financial guidance for the first fiscal quarter ending December 30, 2007.

The following statements are forward looking and actual results may differ materially. Please see "Note Regarding Forward-Looking Statements" at the end of this news release for a description of certain risk factors and Qualcomm's annual and quarterly reports on file with the Securities and Exchange Commission (SEC) for a more complete description of risks that may affect the forward looking statements.

Pro Forma Defined

MONTREAL, December 20 /PRNewswire/ --

- Introduces a Simpler Process Better Aligned with Industry Practices for 2008

Sipro Lab Telecom, the administrator of the G.729 Patent Pool which represents the essential IPR and has contributed to this popular communications standard developed by the G.729 Consortium members: France Telecom, Nippon Telegraph and Telephone Corporation, Mitsubishi Electric Corporation, and Universite de Sherbrooke, announced today that the patent royalty pricing options available to end-product manufacturers will be modified as of January 1st, 2008.

LONDON and CAMBRIDGE, England, December 20 /PRNewswire/ --

- ATRIPLA is a Landmark Achievement of Two Co-operating Companies

ATRIPLA (600 mg efavirenz / 200 mg emtricitabine / 245 mg tenofovir disoproxil as fumarate), launched today in the UK, is the first and only complete HIV treatment in one pill once-daily for virologically suppressed adults, and represents a new era in HIV therapy for these patients. (1,2) In a unique collaboration, two companies - Bristol-Myers Squibb and Gilead Sciences - have come together to develop a single treatment to improve the lives of people with HIV. ATRIPLA offers virologically suppressed adults effective and discreet HIV treatment in one pill, once daily.(2-5)